Literature DB >> 36266363

SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling.

Bao Zhao1,2, Weipeng Gong1, Anjun Ma3, Jianwen Chen1, Maria Velegraki2, Hong Dong1, Zihao Liu1, Lingling Wang2,4, Tamio Okimoto2,5, Devin M Jones1, Yu L Lei6, Meixiao Long2,4, Kenneth J Oestreich1, Qin Ma2,3, Gang Xin1,2, David P Carbone2,5, Kai He2,5, Zihai Li2, Haitao Wen7,8.   

Abstract

Dysfunctional CD8+ T cells, which have defective production of antitumor effectors, represent a major mediator of immunosuppression in the tumor microenvironment. Here, we show that SUSD2 is a negative regulator of CD8+ T cell antitumor function. Susd2-/- effector CD8+ T cells showed enhanced production of antitumor molecules, which consequently blunted tumor growth in multiple syngeneic mouse tumor models. Through a quantitative mass spectrometry assay, we found that SUSD2 interacted with interleukin (IL)-2 receptor α through sushi domain-dependent protein interactions and that this interaction suppressed the binding of IL-2, an essential cytokine for the effector functions of CD8+ T cells, to IL-2 receptor α. SUSD2 was not expressed on regulatory CD4+ T cells and did not affect the inhibitory function of these cells. Adoptive transfer of Susd2-/- chimeric antigen receptor T cells induced a robust antitumor response in mice, highlighting the potential of SUSD2 as an immunotherapy target for cancer.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Year:  2022        PMID: 36266363     DOI: 10.1038/s41590-022-01326-8

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   31.250


  50 in total

1.  Selective in vitro growth of T lymphocytes from normal human bone marrows.

Authors:  D A Morgan; F W Ruscetti; R Gallo
Journal:  Science       Date:  1976-09-10       Impact factor: 47.728

2.  Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors.

Authors:  Xinquan Wang; Mathias Rickert; K Christopher Garcia
Journal:  Science       Date:  2005-11-18       Impact factor: 47.728

Review 3.  The role of interleukin-2 during homeostasis and activation of the immune system.

Authors:  Onur Boyman; Jonathan Sprent
Journal:  Nat Rev Immunol       Date:  2012-02-17       Impact factor: 53.106

Review 4.  Tumour-intrinsic resistance to immune checkpoint blockade.

Authors:  Anusha Kalbasi; Antoni Ribas
Journal:  Nat Rev Immunol       Date:  2019-09-30       Impact factor: 53.106

Review 5.  Understanding the tumor immune microenvironment (TIME) for effective therapy.

Authors:  Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

Review 6.  The γc Family of Cytokines: Basic Biology to Therapeutic Ramifications.

Authors:  Warren J Leonard; Jian-Xin Lin; John J O'Shea
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

Review 7.  Acquired Resistance to Immune Checkpoint Inhibitors.

Authors:  Adam J Schoenfeld; Matthew D Hellmann
Journal:  Cancer Cell       Date:  2020-04-13       Impact factor: 31.743

8.  Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells.

Authors:  Matthew E Pipkin; Jilian A Sacks; Fernando Cruz-Guilloty; Mathias G Lichtenheld; Michael J Bevan; Anjana Rao
Journal:  Immunity       Date:  2010-01-21       Impact factor: 31.745

9.  Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo.

Authors:  Vandana Kalia; Surojit Sarkar; Shruti Subramaniam; W Nicholas Haining; Kendall A Smith; Rafi Ahmed
Journal:  Immunity       Date:  2010-01-21       Impact factor: 31.745

Review 10.  Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.

Authors:  Lawrence P Andrews; Hiroshi Yano; Dario A A Vignali
Journal:  Nat Immunol       Date:  2019-10-14       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.